trial

Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses

NCTId NCT06613334
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 200 (estimated)
Sponsored by Centre Hospitalier St Anne
Primary completion 2026-10-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
200 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2024-10-04
Primary completion
2026-10-04
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Blood test: measurement of plasma antipsychotic concentrationVoice interviews and questionnaires carried out via the CALLYOPE application

Sponsors

Centre Hospitalier St AnneLead Sponsor

Investigators

1
Pierre De Maricourt, DrPrincipal Investigator

Sites

2 total
Paris, FranceParis, France

Facts & assertions

4 sourced
Enrollment
200
Phase
NA
Primary Completion Date
2026-10-04
Status
RECRUITING
relationships
The graph out of here
drug
Blood test: measurement of plasma antipsychotic concentration
drug
Voice interviews and questionnaires carried out via the CALLYOPE application
drug
lead_sponsor
Centre Hospitalier St Anne
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Pierre De Maricourt, Dr
person